



*Recent Frontiers of*

# Phytochemicals

Applications in Food, Pharmacy,  
Cosmetics, and Biotechnology



Edited by  
**Siddhartha Pati, Tanmay Sarkar  
and Dibyajit Lahiri**

# Recent Frontiers of Phytochemicals

Applications in Food, Pharmacy, Cosmetics, and Biotechnology

---

This page intentionally left blank

# Recent Frontiers of Phytochemicals

Applications in Food, Pharmacy, Cosmetics,  
and Biotechnology

---

Edited by

**Siddhartha Pati**

NatNov Bioscience Private Limited, Balasore, Odisha, India

**Tanmay Sarkar**

Malda Polytechnic, West Bengal State Council of Technical Education, Government of West Bengal,  
Malda, West Bengal, India

**Dibyajit Lahiri**

Department of Biotechnology, University of Engineering and Management, Kolkata, India



Elsevier  
Radarweg 29, PO Box 211, 1000 AE Amsterdam, Netherlands  
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom  
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States

Copyright © 2023 Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: [www.elsevier.com/permissions](http://www.elsevier.com/permissions).

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

#### Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN: 978-0-443-19143-5

For Information on all Elsevier publications  
visit our website at <https://www.elsevier.com/books-and-journals>

*Publisher:* Candice G. Janco  
*Acquisitions Editor:* Gabriela D. Capille  
*Editorial Project Manager:* Dan Egan  
*Production Project Manager:* R. Vijay Bharath  
*Cover Designer:* Christian J. Bilbow

Typeset by MPS Limited, Chennai, India



29.2.3	Flavonoids	503	31.3.3	Cardiovascular protection	537
29.2.4	Alkaloids	503	31.3.4	Anti-obesity activity	537
29.2.5	Terpenes	503	31.3.5	Anti-diabetes activity	537
29.2.6	Carotenoids	504	31.3.6	Anticancer activity	537
29.2.7	Phytosterols	504	31.3.7	Antimicrobial activity	538
29.3	Phytotherapy	504	31.4	Fortification in the fermentation industry	538
29.4	Phytomedicine	505	31.4.1	Vitamin fortification	539
29.5	SARS-CoV-2	505	31.4.2	Iron fortification	539
References		505	31.4.3	Calcium fortification	539
			31.4.4	Fortification with phenolics	539
<b>30.</b>	<b>Phytochemicals: recent trends and future prospective in COVID-19</b>	<b>511</b>	31.5	Effect of fermentation on phytochemicals	540
	<i>Dhwani Upadhyay, Arti Gaur, Maru Minaxi, Vijay Upadhye and Prasad Andhare</i>		31.6	Use of phytochemicals as a safe fortifying agent	541
30.1	Introduction	511	31.6.1	Cantaloupe ( <i>C. melon</i> ) incorporated into yogurt	541
30.1.1	SARS-CoV-2 and COVID-19	511	31.6.2	Soy isoflavones used in the fermentation of probiotics and beverages	541
30.1.2	Plants' role in COVID-19 treatment	511	31.6.3	Whole-bread preparation using cupuassu ( <i>Theobroma grandiflorum</i> ) peel	541
30.1.3	Phytochemicals and their role in COVID-19	512	31.7	Limitations	542
30.1.4	List of various targetable sites in SARS-CoV-2 infection with human cell	512	31.8	Conclusion	542
30.2	Virus-based targets	513	References		542
30.2.1	Structural-based proteins	513	<b>32.</b>	<b>Molecular docking study of bioactive phytochemicals against infectious diseases</b>	<b>545</b>
30.2.2	Nonstructural proteins	515		<i>Sanjeev Kumar Sahu, Thatikayala Mahender, Iqbal Singh, Pankaj Wadhwa, Paranjeet Kaur and Kuldeep Bansal</i>	
30.3	Host-based targets	516	32.1	Introduction	545
30.3.1	Host proteins	516	32.1.1	Molecular docking	545
30.3.2	Epigenetic mechanism	517	32.2	Molecular docking studies of plant products as anti-coronal agents	546
30.3.3	Pathways	517	32.3	Molecular docking studies of plant products as anti-leishmanial agents	550
30.3.4	Effects of phytochemicals from honey against COVID-19	521	32.4	Molecular docking studies of plant products as antitubercular agents	557
30.4	Conclusion and future prospective	522	32.5	Conclusion	566
References		528	References		566
<b>31.</b>	<b>Phytochemicals—a safe fortification agent in the fermented food industry</b>	<b>535</b>	<b>33.</b>	<b>Phytochemicals in structure-based drug discovery</b>	<b>569</b>
	<i>Renitta Jobby, Sneha P. Nair, Vaishnavi Murugan, Simran Khera and Kanchanlata Tungare</i>			<i>Amit Kumar, Jaya Baranwal, Amalia Di Petrillo, Sonia Floris, Brajesh Barse and Antonella Fais</i>	
31.1	Introduction	535	33.1	Introduction	569
31.2	Types of phytochemicals	535	33.1.1	Phytochemicals—medicinal properties	570
31.2.1	Alkaloids	535			
31.2.2	Polyphenols	536			
31.2.3	Terpenoids	536			
31.2.4	Organosulfur compounds	536			
31.2.5	Phytosterols	536			
31.2.6	Carotenoids	536			
31.2.7	Other phytochemicals	536			
31.3	Health benefits of phytochemicals	536			
31.3.1	Oxidative stress amelioration	537			
31.3.2	Reducing inflammation	537			

33.2	Phytochemicals screening of plant extracts	571	35.3	Phytochemical constituents	605
33.3	Phytochemicals from <i>Phytolacca dioica</i> L. seeds extracts—case study I	574	35.4	Pharmacological potentialities	607
33.4	Phytochemicals composition and biological properties of seed extracts from <i>Washingtonia filifera</i> —case study II	575	35.4.1	Antioxidative potential	607
33.5	Phytochemicals—opportunities and challenges	579	35.4.2	Antimicrobial potential	608
33.5.1	Phytochemicals as vegan food ingredients	579	35.4.3	Wound-healing potential	608
33.5.2	Plant-based ingredients	579	35.4.4	Antidiarrheal property	609
33.5.3	Dietary supplements	580	35.4.5	Anti-ulcer property	609
33.5.4	Effect of COVID-19 on phytochemicals demand	580	35.4.6	Hepatoprotective potential	610
33.5.5	Transfer of phytochemicals into pharmaceuticals—Challenges	580	35.4.7	Antidiabetic potential	610
References		580	35.4.8	Antinociceptive property	610
			35.4.9	Anti-cancerous property	611
<b>34.</b>	<b>Modulation of drug resistance in leukemia using phytochemicals: an <i>in-silico</i>, <i>in-vitro</i>, and <i>in-vivo</i> approach</b>	<b>583</b>	35.5	Conclusion and future perspective	611
	<i>Urja Desai, Medha Pandya, Hiram Saiyed and Rakesh Rawal</i>		References		611
34.1	Introduction	583	<b>36.</b>	<b>Bioactivity of essential oils and its medicinal applications</b>	<b>617</b>
34.2	Drug resistance: therapeutic failure in leukemia	585		<i>Abdel Rahman Al Tawaha, Rose Abukhader, Ali Qaisi, Abhijit Dey, Abdel Razzaq Al-Tawaha and Iftikhar Ali</i>	
34.2.1	Proteins/genes responsible for drug-resistance leukemia	586	36.1	Introduction	617
34.3	Combination index method and synergism	587	36.2	Chemical structure of flavonoids	618
34.4	Phytochemicals as chemosensitizer and modulators	588	36.3	Flavonoids activity against multidrug-resistant microbes	619
34.4.1	Computational approach to target multidrug resistance	588	36.3.1	Inhibitory activity against cell envelope synthesis	620
34.4.2	In vitro analysis of phytochemicals as multidrug resistance reversal	590	36.3.2	Inhibitory activity against DNA synthesis	621
34.4.3	In vivo analysis of phytochemicals as multidrug resistance-reversing agents	593	36.3.3	Inhibitory activity against ATP synthesis	622
34.5	Conclusions and future prospects	594	36.3.4	Inhibitory activity against bacterial toxins	622
Acknowledgment		595	36.3.5	Inhibitory activity against biofilm formation	623
References		595	36.3.6	Membrane-disrupting activities	624
<b>35.</b>	<b>Phytochemical and bioactive potentialities of <i>Melastoma malabathricum</i></b>	<b>601</b>	36.3.7	Inhibitory activity against efflux pumps	624
	<i>Mansi Tiwari, Mridula Saikia Barooah and Deepjyoti Bhuyan</i>		36.3.8	Inhibitory activity against bacterial motility	625
35.1	Introduction	601	36.4	Conclusion	625
35.2	Ethno-medicinal practices	602	Ethics declarations	625	
			Ethical approval	625	
			Consent to participate	626	
			Consent to publish	626	
			Authors contributions	626	
			Funding	626	
			Competing interests	626	
			Availability of data and materials	626	
			References	626	
			<b>37.</b>	<b>Essential oils as anticancer agents</b>	<b>629</b>
				<i>Vilas Jagatap, Iqrar Ahmad, Aakruti Kaikini and Harun Patel</i>	
			37.1	Introduction	629

# Modulation of drug resistance in leukemia using phytochemicals: *an in-silico, in-vitro, and in-vivo* approach

Urja Desai<sup>1</sup>, Medha Pandya<sup>2</sup>, Hiram Saiyed<sup>1</sup> and Rakesh Rawal<sup>3</sup>

<sup>1</sup>Department of Zoology, Biomedical Technology and Human Genetics, School of Sciences, Gujarat University, Ahmedabad, Gujarat, India,

<sup>2</sup>Department of Life Sciences, Maharaja Krishnakumarsinhji Bhavnagar University, Bhavnagar, Gujarat, India, <sup>3</sup>Department of Life Sciences, School of Sciences, Gujarat University, Ahmedabad, Gujarat, India

### 34.1 Introduction

Leukemia is an uncontrolled proliferation of blood cells. Leukemia means “white blood” (leukos, “white”; haima, “blood”), because a delay in the maturation of the transit-amplifying cells causes a significant increase in immature white blood cells to circulate, turning the blood from red to creamy white. The hallmarks of leukemogenesis encompass recurrent nonrandom chromosomal translocations (Daga et al., 2018). Leukemia is classified clinically or pathologically into acute and chronic forms based on how rapidly the disease develops and the kind of blood cell involved (Vincent et al., 2001). There are mainly four types of leukemia: acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), and acute myelogenous leukemia (AML). Many of the outstanding triumphs in cancer treatment have resulted from novel investigations and trials in leukemia. These include combination chemotherapy, stem cell transplantation, “differentiation” therapy, monoclonal antibody therapy, and targeted treatment (Greaves, 2016). Doxorubicin, cytarabine, ibritinib, idelalisib, rituximab, nilotinib, and imatinib are among the most commonly used chemotherapeutic drugs in the treatment of leukemia. The study shows that doctors are preferring to use chemotherapy or hematopoietic stem cell transplantation (HSCT), and the major issue with this treatment is that leukemia cells can easily relapse after the treatment. The characteristics of leukemia have become more advanced in recent years, and the treatment of this disease must also be more advanced. In addition, organ transplantation can be a good option, and they will have a lifelong risk of immunosuppression. Additionally, the effect of HSCT can be dangerous, and there is proof that “the donor-derived immune system” can easily attack the “recipient’s leukemic cells.” After the relapse of the HSCT, the chemotherapy control procedure is utilized to mitigate the effect. The killer immunoglobulin receptor and KIR ligand interact and allow the donor’s T cells to recognize the antigens related to leukemia (Maacha et al., 2019). However, it happens much too often that leukemia escapes control after HSTC and uses chemotherapy to control the disease although acute leukemia shares several mechanisms of immune evasion that can be found in solid tumors. Unfortunately, hematological malignancies have less research in this area. A deeper understanding of this process is required to create an effective and reasonable immunotherapy for acute leukemia.

Resistance to chemotherapy is one of the most difficult challenges in cancer treatment. Ninety percent of cancer-related mortality is caused by the emergence of drug resistance, which renders chemotherapeutic drugs useless. Drug resistance is the ability of cancer cells to decrease the effectiveness and potency of chemotherapy agents (Nikolaou et al., 2018). Intrinsic resistance, which occurs in cancer when malignant cells develop resistance without having previously been exposed to chemotherapeutic drugs, causes a subpar response to initial therapy (Gottesman, 2002). In some situations, cancer cells initially respond well to chemotherapy but thereafter have a poor response because they have acquired resistance (acquired resistance). Prior studies on cell lines and animal models demonstrated that drug resistance in cancer may be gained by a variety of mechanisms, including drug efflux via the ATP-binding cassette (ABC) transporter, changing the expression of proteins targeted by anticancer medicines, drug detoxification, and evasion of apoptosis (Aris, 2000).